The 7 major keloid markets reached a value of USD 242.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 356.3 Million by 2035, exhibiting a growth rate (CAGR) of 3.53% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 242.8 Million |
Market Forecast in 2035
|
USD 356.3 Million |
Market Growth Rate 2025-2035
|
3.53% |
Prevalence Cases in 2024 | 19,535,019 |
Prevalence Cases in 2035 | 21,113,350 |
The keloid market has been comprehensively analyzed in IMARC's new report titled "Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Keloid refers to a medical condition that occurs when an excess amount of collagen, a protein that forms the connective tissue in the skin, is produced during the healing process of a wound or injury. The excess collagen results in the development of raised, thick, and often irregular scar that extends beyond the borders of the original wound. These scars may range in size from a few millimeters to several centimeters and can be pink, red, brown, or flesh-colored. Keloids may be itchy or tender, and they can cause discomfort or pain. In addition to physical symptoms, they can also lead to emotional distress due to their unsightly appearance and the social stigma associated with them. The diagnosis of the ailment is usually based on a physical exam and medical history. A dermatologist or healthcare provider will typically examine the keloid and surrounding skin for characteristic signs, such as raised and shiny scars that extend beyond the original wound site. The doctor may also enquire about the patient's medical history, including previous injuries or surgeries, and family history of keloids. In some cases, a biopsy may be performed to confirm the diagnosis and rule out other skin conditions. Numerous imaging tests, such as ultrasound, MRI, CT scans, etc., are utilized to evaluate the extent of the keloid.
The increasing occurrences of various skin injuries, including surgical scars, burns, acne, deep cuts, etc., are primarily driving the keloid market. Besides this, the growing prevalence of several cosmetic procedures, such as piercings and tattoos, which can potentially result in keloid formation, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroid injections for reducing the size of the keloid, making them less noticeable, is creating a positive outlook for the market. Apart from this, the inflating demand for cryotherapy, which involves freezing the keloids with liquid nitrogen, thereby causing the keloid tissue to break down and eventually fall off, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced diagnostic techniques, such as multiphoton microscopy and optical coherence tomography, since they provide high-resolution images of the skin and can help identify the location as well as the extent of keloids, is also bolstering the market growth. Moreover, the emerging popularity of radiofrequency ablation on account of its numerous benefits over traditional surgical excision, including reduced scarring, improved function, and fewer complications, is expected to drive the keloid market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the keloid market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for keloid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keloid market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current keloid marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Kenalog-10 Injection (Triamcinolone Acetonide) | Bristol-Myers Squibb |
Aristospan (Triamcinolone Hexacetonide) | Sandoz |
Aldara (Imiquimod 5% cream) | 3M Health Care |
Adrucil (5-Fluorouracil) | Teva Pharmaceuticals |
Verelan (Verapamil) | UCB |
Jelmyto (Mitomycin C) | UroGen Pharma |
Bleo 15k (Bleomycin) | Amneal Biosciences |
Botox (onabotulinumtoxinA)/botulinum toxin | Allergan |
Tranilast (Rizaben) | Kissei Pharmaceuticals |
TOP-N44 | Topadur Pharma |
INV 001 | Innovo Therapeutics |
AIV001 | AiViva BioPharma |
STP 705 | Sirnaomics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Keloid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies